# Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)

> **NCT05018416** · PHASE2 · COMPLETED · sponsor: **Prokidney** · enrollment: 53 (actual)

## Conditions studied

- Chronic Kidney Diseases
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus

## Interventions

- **BIOLOGICAL:** Renal Autologous Cell Therapy (REACT)

## Key facts

- **NCT ID:** NCT05018416
- **Lead sponsor:** Prokidney
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-27
- **Primary completion:** 2025-05-20
- **Final completion:** 2025-05-20
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05018416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05018416, "Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05018416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*